Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing

Core Insights - SOPHiA GENETICS has achieved a significant milestone in the global adoption of its cancer testing applications, with 37 institutions adopting the MSK-ACCESS® and MSK-IMPACT® applications powered by SOPHiA DDM™ [1][5][8] Group 1: Adoption and Impact - 34 out of the 37 institutions have adopted the MSK-ACCESS® application within 10 months of its launch, enabling decentralized Liquid Biopsy testing [5] - The decentralized deployment allows institutions to provide less-invasive genomic testing options, resulting in lower costs and faster turnaround times while retaining control over patient data [5] - Notable institutions adopting these applications include Heidelberg University Hospital, Biopticka Laboratory, and Jewish General Hospital [6][7] Group 2: Collaborations and Future Prospects - SOPHiA GENETICS partnered with Memorial Sloan Kettering Cancer Center in 2023 to enhance cancer testing capabilities globally [8] - A definitive partnership with AstraZeneca was announced in October 2024 to accelerate the deployment of MSK-ACCESS® [8] - These collaborations aim to transform cancer research by leveraging real-world data and advanced technology [8] Group 3: Expert Endorsements - Professor Umberto Malapelle from the University Federico II of Naples supports the new applications for cancer research, highlighting the collaborative potential of SOPHiA GENETICS [2][3] - Ross Muken, President of SOPHiA GENETICS, emphasized the importance of bringing advanced technology to global organizations for improved healthcare [4]